Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E11.50 EPS (ttm)55.71 Insider Own1.60% Shs Outstand105.00M Perf Week0.21%
Market Cap68.68B Forward P/E14.79 EPS next Y43.32 Insider Trans-23.86% Shs Float102.21M Perf Month-2.25%
Income6.21B PEG2.88 EPS next Q9.30 Inst Own89.00% Short Float1.33% Perf Quarter19.96%
Sales12.38B P/S5.55 EPS this Y65.30% Inst Trans2.44% Short Ratio1.75 Perf Half Y32.63%
Book/sh144.07 P/B4.45 EPS next Y-25.41% ROA34.20% Target Price677.04 Perf Year15.43%
Cash/sh36.49 P/C17.56 EPS next 5Y4.00% ROE51.40% 52W Range441.00 - 686.62 Perf YTD32.66%
Dividend- P/FCF40.56 EPS past 5Y40.80% ROI23.90% 52W High-6.66% Beta0.17
Dividend %- Quick Ratio3.20 Sales past 5Y15.70% Gross Margin86.80% 52W Low45.33% ATR16.52
Employees9123 Current Ratio3.60 Sales Q/Q163.20% Oper. Margin53.90% RSI (14)46.98 Volatility2.03% 2.37%
OptionableYes Debt/Eq0.18 EPS Q/Q267.50% Profit Margin50.10% Rel Volume0.81 Prev Close651.88
ShortableYes LT Debt/Eq0.13 EarningsAug 05 BMO Payout0.00% Avg Volume775.91K Price640.89
Recom2.00 SMA20-3.35% SMA502.79% SMA20020.92% Volume666,652 Change-1.69%
Jun-29-21Initiated H.C. Wainwright Buy $703
Jan-25-21Upgrade BMO Capital Markets Market Perform → Outperform $630
Jan-13-21Upgrade The Benchmark Company Hold → Buy $590
Jan-08-21Upgrade Citigroup Neutral → Buy $635 → $575
Oct-05-20Upgrade Cantor Fitzgerald Neutral → Overweight $690
Aug-20-20Downgrade The Benchmark Company Buy → Hold
Jul-09-20Upgrade SunTrust Hold → Buy $400 → $750
May-26-20Upgrade Wells Fargo Equal Weight → Overweight $559 → $734
Apr-28-20Downgrade Citigroup Buy → Neutral $540 → $575
Apr-17-20Upgrade The Benchmark Company Hold → Buy $655
Apr-08-20Initiated The Benchmark Company Hold
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $530
Feb-26-20Upgrade Canaccord Genuity Hold → Buy $550
Feb-26-20Downgrade Robert W. Baird Outperform → Neutral $410
Feb-25-20Upgrade Jefferies Hold → Buy $355 → $492
Feb-11-20Upgrade Argus Hold → Buy $430
Dec-24-19Initiated Raymond James Mkt Perform
Dec-16-19Downgrade Evercore ISI Outperform → In-line
Dec-13-19Upgrade Credit Suisse Neutral → Outperform $400
Sep-21-21 12:59AM  
Sep-20-21 05:50PM  
01:42PM  
06:45AM  
Sep-19-21 11:30AM  
Sep-18-21 05:57AM  
Sep-17-21 03:59PM  
03:56PM  
02:09PM  
12:12PM  
Sep-16-21 11:28AM  
08:39AM  
06:00AM  
Sep-15-21 01:51PM  
12:24PM  
11:30AM  
09:52AM  
07:57AM  
07:53AM  
07:40AM  
07:38AM  
07:27AM  
Sep-14-21 06:06PM  
05:33PM  
11:27AM  
Sep-13-21 05:50PM  
10:46AM  
Sep-11-21 06:12AM  
Sep-09-21 02:24PM  
Sep-08-21 04:05PM  
01:37PM  
Sep-07-21 02:12PM  
10:50AM  
09:48AM  
09:10AM  
09:06AM  
Sep-03-21 01:58PM  
Sep-02-21 02:18PM  
12:00PM  
10:26AM  
06:00AM  
Sep-01-21 02:14PM  
10:44AM  
Aug-31-21 10:46AM  
Aug-30-21 02:06PM  
11:30AM  
11:02AM  
10:51AM  
07:44AM  
06:58AM  
12:59AM  
Aug-27-21 02:07PM  
12:50PM  
12:16PM  
07:10AM  
05:55AM  
Aug-26-21 12:56PM  
Aug-25-21 01:38PM  
11:31AM  
11:22AM  
07:16AM  
Aug-24-21 02:16PM  
12:57PM  
09:57AM  
07:00AM  
Aug-23-21 01:57PM  
11:20AM  
Aug-20-21 02:54PM  
01:56PM  
09:47AM  
09:03AM  
09:01AM  
07:00AM  
06:48AM  
03:12AM  
Aug-19-21 03:01PM  
11:55AM  
09:26AM  
Aug-18-21 04:11PM  
02:06PM  
11:50AM  
11:03AM  
10:32AM  
08:59AM  
06:50AM  
Aug-17-21 08:42PM  
03:01PM  
06:17AM  
Aug-16-21 03:53PM  
03:02PM  
01:50PM  
Aug-14-21 09:01AM  
Aug-13-21 02:05PM  
Aug-12-21 02:11PM  
11:31AM  
11:30AM  
11:05AM  
Aug-11-21 02:20PM  
10:11AM  
Aug-10-21 09:39AM  
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COLES N ANTHONYDirectorSep 15Option Exercise365.9911,9484,372,80712,850Sep 17 04:01 PM
COLES N ANTHONYDirectorSep 15Sale658.9811,9487,873,484902Sep 17 04:01 PM
Zoghbi Huda YDirectorSep 14Option Exercise391.92998391,1361,889Sep 15 04:03 PM
Zoghbi Huda YDirectorSep 14Sale650.00998648,700891Sep 15 04:03 PM
Zoghbi Huda YDirectorSep 13Option Exercise391.922784893Sep 15 04:03 PM
Tessier-Lavigne MarcDirectorSep 13Option Exercise273.6712,7503,489,29214,828Sep 15 04:02 PM
BROWN MICHAEL SDirectorSep 13Option Exercise405.069,7043,930,68410,595Sep 15 04:03 PM
Tessier-Lavigne MarcDirectorSep 13Sale641.7112,7508,181,8272,078Sep 15 04:02 PM
Zoghbi Huda YDirectorSep 13Sale651.1021,302891Sep 15 04:03 PM
BROWN MICHAEL SDirectorSep 13Sale648.169,7046,289,792891Sep 15 04:03 PM
GOLDSTEIN JOSEPH LDirectorSep 10Option Exercise380.952,479944,3758,370Sep 13 04:01 PM
GOLDSTEIN JOSEPH LDirectorSep 10Sale650.002,4791,611,3505,891Sep 13 04:01 PM
McCourt MarionEVP CommercialSep 01Option Exercise342.931,000342,93018,038Sep 03 04:03 PM
RYAN ARTHUR FDirectorSep 01Sale676.2810067,62823,291Sep 03 04:04 PM
McCourt MarionEVP CommercialSep 01Sale674.721,000674,72017,038Sep 03 04:03 PM
Landry Robert EEVP Finance CFOAug 31Option Exercise555.671,000555,67026,903Sep 01 04:05 PM
SING GEORGE LDirectorAug 30Sale671.09550369,100750Aug 30 04:26 PM
SING GEORGE LDirectorAug 30Sale672.501,000672,50042,858Aug 30 04:26 PM
POON CHRISTINE ADirectorAug 27Option Exercise57.1115,000856,65016,681Aug 31 04:03 PM
POON CHRISTINE ADirectorAug 27Sale668.0915,00010,021,4061,681Aug 31 04:03 PM
SING GEORGE LDirectorAug 26Sale672.00150100,8001,000Aug 30 04:26 PM
VAGELOS P ROYDirectorAug 25Option Exercise179.1375,00013,434,750366,090Aug 27 04:01 PM
LAROSA JOSEPH JEVP General Counsel and SecretAug 23Sale661.843,4252,266,81713,182Aug 24 04:06 PM
Fenimore Christopher R.SVP ControllerAug 23Sale655.314,7813,133,03727,739Aug 24 04:04 PM
Fenimore Christopher R.SVP ControllerAug 20Option Exercise179.1313,5002,418,25532,520Aug 24 04:04 PM
LAROSA JOSEPH JEVP General Counsel and SecretAug 20Option Exercise179.1310,0001,791,30023,182Aug 24 04:06 PM
SCHLEIFER LEONARD SPresident & CEOAug 19Sale660.0310,0006,600,30021,178Aug 20 04:02 PM
COLES N ANTHONYDirectorAug 18Option Exercise345.475,1001,761,8976,002Aug 19 04:04 PM
SCHLEIFER LEONARD SPresident & CEOAug 18Sale650.03200,000130,006,000304,746Aug 20 04:02 PM
VAGELOS P ROYDirectorAug 18Sale650.0410,0396,525,75237,747Aug 19 04:05 PM
COLES N ANTHONYDirectorAug 18Sale650.005,1003,315,000902Aug 19 04:04 PM
COLES N ANTHONYDirectorAug 17Option Exercise345.47900310,9231,802Aug 19 04:04 PM
COLES N ANTHONYDirectorAug 17Sale650.00900585,000902Aug 19 04:04 PM
Bassler Bonnie LDirectorAug 16Option Exercise376.691,219459,1852,110Aug 17 04:16 PM
YANCOPOULOS GEORGEPresident and Chief ScientificAug 16Sale625.2949,22730,781,138887,483Aug 17 04:13 PM
SCHLEIFER LEONARD SPresident & CEOAug 16Sale624.3610,0006,243,61431,178Aug 17 04:42 PM
SING GEORGE LDirectorAug 16Sale627.501,000627,5002,050Aug 17 04:17 PM
SING GEORGE LDirectorAug 16Sale630.00705444,15043,858Aug 17 04:17 PM
Bassler Bonnie LDirectorAug 16Sale630.001,219767,970891Aug 17 04:16 PM
COLES N ANTHONYDirectorAug 13Option Exercise345.472,000690,9402,902Aug 16 04:04 PM
YANCOPOULOS GEORGEPresident and Chief ScientificAug 13Sale625.00773483,125936,710Aug 17 04:13 PM
COLES N ANTHONYDirectorAug 13Sale625.002,0001,250,000902Aug 16 04:04 PM
SING GEORGE LDirectorAug 13Sale620.00500310,00044,563Aug 13 05:19 PM
SING GEORGE LDirectorAug 12Sale611.001,000611,00045,063Aug 13 05:19 PM
SING GEORGE LDirectorAug 11Sale620.00300186,0003,050Aug 13 05:19 PM
SING GEORGE LDirectorAug 11Sale620.502,0001,241,00046,063Aug 13 05:19 PM
SING GEORGE LDirectorAug 10Sale613.852,6001,596,01048,063Aug 10 05:00 PM
Landry Robert EEVP Finance CFOAug 10Sale611.90537328,59325,903Aug 10 05:55 PM
Van Plew Daniel PEVP & General Mgr, IndustrialAug 10Sale611.866,6034,040,10526,931Aug 10 05:54 PM
Van Plew Daniel PEVP & General Mgr, IndustrialAug 09Option Exercise270.4325,0006,760,75051,931Aug 10 05:54 PM
Landry Robert EEVP Finance CFOAug 09Option Exercise381.923,0001,145,76028,903Aug 10 05:55 PM
BROWN MICHAEL SDirectorAug 09Sale612.381,6871,033,0857,662Aug 10 05:00 PM
Landry Robert EEVP Finance CFOAug 09Sale617.83364224,89125,903Aug 10 05:55 PM
Landry Robert EEVP Finance CFOAug 06Option Exercise381.922,000763,84027,903Aug 10 05:55 PM
SCHLEIFER LEONARD SPresident & CEOAug 06Option Exercise52.03400,00020,812,000596,176Aug 10 05:05 PM
SING GEORGE LDirectorAug 06Sale612.42350214,3473,350Aug 10 05:00 PM
SING GEORGE LDirectorAug 06Sale611.384,0002,445,52050,663Aug 10 05:00 PM
Bassler Bonnie LDirectorAug 05Option Exercise391.922,5591,002,9233,450Aug 06 04:02 PM
YANCOPOULOS GEORGEPresident and Chief ScientificAug 05Sale600.0650,00030,003,000937,483Aug 06 04:03 PM
Bassler Bonnie LDirectorAug 05Sale600.002,5591,535,400891Aug 06 04:02 PM
McCourt MarionEVP CommercialAug 02Option Exercise342.931,000342,93018,038Aug 04 04:03 PM
RYAN ARTHUR FDirectorAug 02Sale577.9510057,79523,391Aug 04 04:05 PM
McCourt MarionEVP CommercialAug 02Sale577.121,000577,12017,038Aug 04 04:03 PM
LAROSA JOSEPH JEVP General Counsel and SecretJul 06Sale580.003,3981,970,84013,182Jul 07 04:01 PM
LAROSA JOSEPH JEVP General Counsel and SecretJul 02Option Exercise179.1310,0001,791,30023,182Jul 07 04:01 PM
RYAN ARTHUR FDirectorJul 01Sale564.5010056,45023,491Jul 02 04:02 PM
BROWN MICHAEL SDirectorJun 25Option Exercise371.402,084773,9982,975Jun 28 04:01 PM
BROWN MICHAEL SDirectorJun 25Sale549.002,0841,144,116891Jun 28 04:01 PM
YANCOPOULOS GEORGEPresident and Chief ScientificJun 21Sale538.9080,00043,112,1412,108Jun 23 04:02 PM
BROWN MICHAEL SDirectorJun 14Option Exercise371.401,700631,3802,591Jun 16 04:02 PM
RYAN ARTHUR FDirectorJun 14Sale524.7610052,47623,591Jun 16 04:03 PM
BROWN MICHAEL SDirectorJun 14Sale525.001,700892,500891Jun 16 04:02 PM
GOLDSTEIN JOSEPH LDirectorJun 07Option Exercise374.121,930722,0527,821Jun 08 04:03 PM
McCourt MarionEVP CommercialJun 07Option Exercise342.931,000342,93018,038Jun 08 04:02 PM
McCourt MarionEVP CommercialJun 07Sale511.651,000511,65017,038Jun 08 04:02 PM
GOLDSTEIN JOSEPH LDirectorJun 07Sale525.001,9301,013,2505,891Jun 08 04:03 PM
STAHL NEILEVP Research and DevelopmentMay 17Sale519.4617,5219,101,46024,280May 18 04:04 PM
STAHL NEILEVP Research and DevelopmentMay 14Option Exercise148.8752,5007,815,57564,280May 18 04:04 PM
McCourt MarionEVP CommercialMay 07Option Exercise342.931,000342,93018,038May 10 04:02 PM
McCourt MarionEVP CommercialMay 07Sale495.631,000495,63017,038May 10 04:02 PM
VAGELOS P ROYDirectorFeb 23Option Exercise52.03250,00013,007,500487,088Feb 24 04:02 PM
RYAN ARTHUR FDirectorFeb 01Sale506.9210050,69223,691Feb 02 04:06 PM
BROWN MICHAEL SDirectorJan 25Option Exercise380.952,480944,7563,371Jan 27 04:06 PM
BROWN MICHAEL SDirectorJan 25Sale554.322,4801,374,714891Jan 27 04:06 PM
RYAN ARTHUR FDirectorJan 04Sale483.6010048,36023,543Jan 05 04:09 PM
YANCOPOULOS GEORGEPresident and Chief ScientificDec 30Option Exercise52.03398,07920,712,050908,303Dec 31 05:30 PM
RYAN ARTHUR FDirectorDec 01Sale520.4810052,04823,643Dec 02 04:09 PM
MURPHY ANDREW JEVP ResearchNov 17Sale542.736,6283,597,18847,136Nov 18 04:02 PM
MURPHY ANDREW JEVP ResearchNov 16Option Exercise30.6313,736420,73460,872Nov 18 04:02 PM
COLES N ANTHONYDirectorNov 13Option Exercise345.47113,800654Nov 13 05:57 PM
RYAN ARTHUR FDirectorNov 02Sale548.5410054,85423,743Nov 03 05:22 PM
MURPHY ANDREW JEVP ResearchOct 22Option Exercise38.565,185199,92647,136Oct 23 04:02 PM
McCourt MarionSVP CommercialOct 05Option Exercise342.931,000342,93014,963Oct 06 04:07 PM
GOLDSTEIN JOSEPH LDirectorOct 05Option Exercise520.019,2124,790,33214,855Oct 06 04:09 PM
GOLDSTEIN JOSEPH LDirectorOct 05Sale600.009,2125,527,2005,643Oct 06 04:09 PM
McCourt MarionSVP CommercialOct 05Sale600.001,000600,00013,963Oct 06 04:07 PM
RYAN ARTHUR FDirectorOct 01Sale558.1310055,81328,343Oct 05 04:13 PM
BROWN MICHAEL SDirectorSep 22Option Exercise378.775,0901,927,9175,733Sep 23 04:01 PM
BROWN MICHAEL SDirectorSep 22Sale552.361,000552,3609,349Sep 23 04:01 PM
BROWN MICHAEL SDirectorSep 22Sale552.365,0902,811,512643Sep 23 04:01 PM